129 related articles for article (PubMed ID: 10664160)
1. Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits.
Kanda A; Nakao S; Tsuyama S; Murata F; Kanzaki T
Virchows Arch; 2000 Jan; 436(1):36-42. PubMed ID: 10664160
[TBL] [Abstract][Full Text] [Related]
2. Cellular and tissue localization of globotriaosylceramide in Fabry disease.
Askari H; Kaneski CR; Semino-Mora C; Desai P; Ang A; Kleiner DE; Perlee LT; Quezado M; Spollen LE; Wustman BA; Schiffmann R
Virchows Arch; 2007 Oct; 451(4):823-34. PubMed ID: 17674039
[TBL] [Abstract][Full Text] [Related]
3. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients.
Navarro C; Teijeira S; Dominguez C; Fernandez JM; Rivas E; Fachal C; Barrera S; Rodriguez C; Iranzo P
Acta Neuropathol; 2006 Feb; 111(2):178-85. PubMed ID: 16463201
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
[TBL] [Abstract][Full Text] [Related]
6. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
Biancini GB; Vanzin CS; Rodrigues DB; Deon M; Ribas GS; Barschak AG; Manfredini V; Netto CB; Jardim LB; Giugliani R; Vargas CR
Biochim Biophys Acta; 2012 Feb; 1822(2):226-32. PubMed ID: 22085605
[TBL] [Abstract][Full Text] [Related]
7. Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease.
Yokoi T; Kobayashi H; Shimada Y; Eto Y; Ishige N; Kitagawa T; Otsu M; Nakauchi H; Ida H; Ohashi T
J Gene Med; 2011 May; 13(5):262-8. PubMed ID: 21520359
[TBL] [Abstract][Full Text] [Related]
8. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
9. A Case of Fabry Disease With Lacrimal Gland Involvement.
Bruce CN; Mancera N; Grover A; Esmaili N
Ophthalmic Plast Reconstr Surg; 2023 Mar-Apr 01; 39(2):e52-e55. PubMed ID: 36728127
[TBL] [Abstract][Full Text] [Related]
10. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
Yam GH; Zuber C; Roth J
FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
[TBL] [Abstract][Full Text] [Related]
11. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
12. Adipocytes participate in storage in α-galactosidase deficiency (Fabry disease).
Hůlková H; Elleder M
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3(Suppl 3):S297-300. PubMed ID: 20628902
[TBL] [Abstract][Full Text] [Related]
13. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature.
Thurberg BL; Politei JM
Hum Pathol; 2012 Apr; 43(4):610-4. PubMed ID: 22078290
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
Ashe KM; Budman E; Bangari DS; Siegel CS; Nietupski JB; Wang B; Desnick RJ; Scheule RK; Leonard JP; Cheng SH; Marshall J
Mol Med; 2015 Apr; 21(1):389-99. PubMed ID: 25938659
[TBL] [Abstract][Full Text] [Related]
16. Identification of lysosomal and extralysosomal globotriaosylceramide (Gb3) accumulations before the occurrence of typical pathological changes in the endomyocardial biopsies of Fabry disease patients.
Hsu MJ; Chang FP; Lu YH; Hung SC; Wang YC; Yang AH; Lee HJ; Sung SH; Wang YF; Yu WC; Hsu TR; Huang PH; Chang SK; Dzhagalov I; Hsu CL; Niu DM
Genet Med; 2019 Jan; 21(1):224-232. PubMed ID: 29875425
[TBL] [Abstract][Full Text] [Related]
17. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease.
Itier JM; Ret G; Viale S; Sweet L; Bangari D; Caron A; Le-Gall F; Bénichou B; Leonard J; Deleuze JF; Orsini C
J Inherit Metab Dis; 2014 Nov; 37(6):1013-22. PubMed ID: 24850378
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Human Dermal Fibroblasts in Fabry Disease.
Lakomá J; Donadio V; Liguori R; Caprini M
J Cell Physiol; 2016 Jan; 231(1):192-203. PubMed ID: 26058984
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of Fabry disease endothelial cells with an extended lifespan.
Shen JS; Meng XL; Schiffmann R; Brady RO; Kaneski CR
Mol Genet Metab; 2007; 92(1-2):137-44. PubMed ID: 17644384
[TBL] [Abstract][Full Text] [Related]
20. Immunoelectron-microscopic detection of globotriaosylceramide accumulated in the skin of patients with Fabry disease.
Kanekura T; Fukushige T; Kanda A; Tsuyama S; Murata F; Sakuraba H; Kanzaki T
Br J Dermatol; 2005 Sep; 153(3):544-8. PubMed ID: 16120140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]